LRRK2 anticorps (AA 931-962)

N° du produit ABIN1882109

Il existe 4+ publications pour ce produit. L’anticorps anti-LRRK2 Polyclonal Lapin est utilisé pour la détection de LRRK2 dans des échantillons de Humain. Il a été validé pour WB et IHC (p).

Aperçu rapide pour LRRK2 anticorps (AA 931-962) (ABIN1882109)

Antigène: LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp LRRK2 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: RB7199

Détail du produit anti-LRRK2 anticorps

Épitope: AA 931-962

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogène: This PARK8(LRRK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 931-962 amino acids from human PARK8(LRRK2).

Isotype: Ig Fraction

Information d'application

Indications d'application: WB: 1:1000. WB: 1:1000. IHC-P: 1:50~100

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Date de péremption: 6 months

Références pour anticorps anti-LRRK2 (ABIN1882109)

Biskup, Moore, Rea, Lorenz-Deperieux, Coombes, Dawson, Dawson, West: "Dynamic and redundant regulation of LRRK2 and LRRK1 expression." dans: BMC neuroscience, Vol. 8, pp. 102, (2008) (PubMed).

Shen: "Protein kinases linked to the pathogenesis of Parkinson's disease." dans: Neuron, Vol. 44, Issue 4, pp. 575-7, (2004) (PubMed).

Wszolek, Pfeiffer, Tsuboi, Uitti, McComb, Stoessl, Strongosky, Zimprich, Müller-Myhsok, Farrer, Gasser, Calne, Dickson: "Autosomal dominant parkinsonism associated with variable synuclein and tau pathology." dans: Neurology, Vol. 62, Issue 9, pp. 1619-22, (2004) (PubMed).

Zimprich, Biskup, Leitner, Lichtner, Farrer, Lincoln, Kachergus, Hulihan, Uitti, Calne, Stoessl, Pfeiffer, Patenge, Carbajal, Vieregge, Asmus, Müller-Myhsok, Dickson, Meitinger, Strom, Wszolek, Gasser: "Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology." dans: Neuron, Vol. 44, Issue 4, pp. 601-7, (2004) (PubMed).

Détails sur LRRK2

Antigène: LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

Autre désignation: PARK8 (LRRK2)

Sujet: Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.

Poids moléculaire: 286103

NCBI Accession: NP_940980

UniProt: Q5S007

Pathways: Regulation of G-Protein Coupled Receptor Protein Signaling, Skeletal Muscle Fiber Development